{"uri": "eng-9427308", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Weight_loss", "type": "wiki", "score": 100, "label": {"eng": "Weight loss"}}, {"uri": "http://en.wikipedia.org/wiki/Obesity", "type": "wiki", "score": 94, "label": {"eng": "Obesity"}}, {"uri": "http://en.wikipedia.org/wiki/Vikings", "type": "wiki", "score": 81, "label": {"eng": "Vikings"}}, {"uri": "http://en.wikipedia.org/wiki/Tolerability", "type": "wiki", "score": 76, "label": {"eng": "Tolerability"}}, {"uri": "http://en.wikipedia.org/wiki/Glucagon-like_peptide-1", "type": "wiki", "score": 70, "label": {"eng": "Glucagon-like peptide-1"}}, {"uri": "http://en.wikipedia.org/wiki/Gastric_inhibitory_polypeptide", "type": "wiki", "score": 67, "label": {"eng": "Gastric inhibitory polypeptide"}}, {"uri": "http://en.wikipedia.org/wiki/Clinical_trial", "type": "wiki", "score": 59, "label": {"eng": "Clinical trial"}}, {"uri": "http://en.wikipedia.org/wiki/Placebo", "type": "wiki", "score": 57, "label": {"eng": "Placebo"}}, {"uri": "http://en.wikipedia.org/wiki/Agonist", "type": "wiki", "score": 53, "label": {"eng": "Agonist"}}, {"uri": "http://en.wikipedia.org/wiki/Side_effect", "type": "wiki", "score": 48, "label": {"eng": "Side effect"}}, {"uri": "http://en.wikipedia.org/wiki/Gastrointestinal_tract", "type": "wiki", "score": 47, "label": {"eng": "Gastrointestinal tract"}}, {"uri": "http://en.wikipedia.org/wiki/Receptor_(biochemistry)", "type": "wiki", "score": 43, "label": {"eng": "Receptor (biochemistry)"}}, {"uri": "http://en.wikipedia.org/wiki/Chief_executive_officer", "type": "wiki", "score": 39, "label": {"eng": "Chief executive officer"}}, {"uri": "http://en.wikipedia.org/wiki/Adverse_event", "type": "wiki", "score": 36, "label": {"eng": "Adverse event"}}, {"uri": "http://en.wikipedia.org/wiki/Dose\u2013response_relationship", "type": "wiki", "score": 32, "label": {"eng": "Dose\u2013response relationship"}}, {"uri": "http://en.wikipedia.org/wiki/Metabolism", "type": "wiki", "score": 30, "label": {"eng": "Metabolism"}}, {"uri": "http://en.wikipedia.org/wiki/Injection_(medicine)", "type": "wiki", "score": 27, "label": {"eng": "Injection (medicine)"}}, {"uri": "http://en.wikipedia.org/wiki/Experiment", "type": "wiki", "score": 25, "label": {"eng": "Experiment"}}, {"uri": "http://en.wikipedia.org/wiki/Metabolic_disorder", "type": "wiki", "score": 24, "label": {"eng": "Metabolic disorder"}}, {"uri": "http://en.wikipedia.org/wiki/Medication", "type": "wiki", "score": 24, "label": {"eng": "Medication"}}], "eventDate": "2024-03-25", "totalArticleCount": 13, "title": {"eng": "Viking Therapeutics reports positive phase 1 obesity drug trial results By Investing.com"}, "summary": {"eng": "SAN DIEGO - Viking Therapeutics, Inc. (NASDAQ: NASDAQ:VKTX) today announced positive outcomes from its Phase 1 clinical trial of VK2735, an oral medication being developed for obesity treatment. The study revealed that after 28 days of treatment, subjects experienced up to 5.3% weight loss from baseline, and up to 3.3% when adjusted for placebo effects.\n\nThe trial, which tested multiple ascending doses of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulino"}, "location": null, "categories": [{"uri": "dmoz/Health/Specific_Substances/Tobacco", "label": "dmoz/Health/Specific Substances/Tobacco", "wgt": 100}, {"uri": "dmoz/Shopping/Health/Conditions_and_Diseases", "label": "dmoz/Shopping/Health/Conditions and Diseases", "wgt": 100}, {"uri": "dmoz/Health/Teen_Health/Drugs_and_Alcohol", "label": "dmoz/Health/Teen Health/Drugs and Alcohol", "wgt": 100}, {"uri": "news/Health", "label": "news/Health", "wgt": 70}], "articleCounts": {"eng": 13}, "sentiment": 0.192156862745098, "wgt": 449020800, "relevance": 2}